Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06324201 · ClinicalTrials.gov registry record
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
A clinical trial of Paroxysmal Atrial Fibrillation, sponsored by Heart Rhythm Clinical and Research Solutions.
- Recruiting
- Registry status
- 250
- Enrollment target
- 20
- Study locations
NCT06324201 is a study of Paroxysmal Atrial Fibrillation that is actively recruiting participants, run by Heart Rhythm Clinical and Research Solutions. The registered enrollment target is 250 participants, below the 849-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06324201, a study of Paroxysmal Atrial Fibrillation, is actively recruiting participants, sponsored by Heart Rhythm Clinical and Research Solutions.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-study per inclusion and exclusion criteria.
Conditions Studied
Interventions
- DEVICE Ablation Procedure
Study Locations (20)
Virginia
- Centra Health, Inc.dba Stroobants Cardiovascular Center - Lynchburg
- Bon Secours Medical Group - Richmond Specialty Care - Richmond
- Valley Health System - Winchester
Alabama
- Arrhythmia Institute at Grandview - Birmingham
- Mobile Cardiology Associates - Mobile
Florida
- Naples Community Hospital - Naples
- Sarasota Memorial Health - Sarasota
Michigan
- Sparrow Clinical Research Institute - Lansing
- Trinity Health-Michigan Heart - Ypsilanti
Ohio
- The Christ Hospital - Cincinnati
- University of Cincinnati - Cincinnati
Pennsylvania
- University of Pennsylvania (UPENN) - Philadelphia
- Allegheny Health - Pittsburgh
Washington
- Multicare Health Systems-Pulse Heart - Puyallup
- Franciscan Heart and Vascular Associates - Tacoma
California
- Community Memorial Health System - Ventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06324201
The ClinicalTrials.gov registry entry for NCT06324201 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 849-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (71% lower). The listed sponsor is Heart Rhythm Clinical and Research Solutions, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Ablation Procedure is the first listed.
NCT06324201 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Virginia, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT06324201 about?
NCT06324201 is a clinical study titled "The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.". Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-s...
What is the current status of trial NCT06324201?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2024-02-27. Estimated completion is 2028-03.
What conditions does trial NCT06324201 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT06324201?
The interventions under investigation include: Ablation Procedure (DEVICE).
Who is sponsoring clinical trial NCT06324201?
This trial is sponsored by Heart Rhythm Clinical and Research Solutions, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06324201 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
STOP AF First Post-Approval Study
RECRUITING
-
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
RECRUITING
-
Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF)
RECRUITING · NA
-
Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.